Research Papers:

SETD7 is a prognosis predicting factor of breast cancer and regulates redox homeostasis

Run Huang, Xiaolin Li, Yang Yu, Lisi Ma, Sixuan Liu, Xiangyun Zong _ and Qi Zheng

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:94080-94090. https://doi.org/10.18632/oncotarget.21583

Metrics: PDF 1963 views  |   HTML 2534 views  |   ?  


Run Huang1,*, Xiaolin Li1,*, Yang Yu2,*, Lisi Ma1, Sixuan Liu1, Xiangyun Zong1 and Qi Zheng3

1Department of Breast Surgery, Shanghai Jiao Tong University Affiliated Shanghai Sixth People’s Hospital, Shanghai 200233, China

2Department of Breast Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, China

3Department of General Surgery, Shanghai Jiao Tong University Affiliated Shanghai Sixth People’s Hospital, Shanghai 200233, China

*These authors have contributed equally to this work

Correspondence to:

Xiangyun Zong, email: [email protected]

Keywords: SETD7, breast cancer, redox homeostasis, reactive oxygen species, oxidative stress

Received: June 30, 2017     Accepted: September 21, 2017     Published: October 06, 2017


SETD7 is a methyltransferase that specifically catalyzes the monomethylation of lysine 4 on histone H3. A variety of studies has revealed the role of SETD7 in posttranslational modifications of non-histone proteins. However, the prognostic value of SETD7 on breast cancer and the ability of SETD7 of regulating intrinsic redox homeostasis has never been investigated. In this study, using The Cancer Genome Atlas (TCGA) database, we revealed that SETD7 was a potential prognostic marker of breast cancer. Median survival time of patients with low SETD7 expression (18.1 years) was twice than that of SETD7 low-expressed patients (9.5 years). We demonstrated that SETD7 promoted tumor cell proliferation and prevented cell apoptosis and that SETD7 delicately maintained the redox homeostasis through regulating the levels of GSH/GSSG and ROS. Further studies indicated that SETD7 was a positive activator of KEAP1-NRF2 pathway. Using dual luciferase assay, we revealed the role of SETD7 as a transcriptional activator of antioxidant enzymes. Downregulation of SETD7 in MCF7 and MDA-MB-231 cells impaired the expression of antioxidant enzymes and induces imbalance of redox status. Together, we proposed SETD7 as a prognostic marker of breast cancer and a novel antioxidant promoter under oxidative stress in breast cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21583